Nasdaq

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life Over 600,000 Japanese patients suffer from ...
Seeking Alpha

Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress ...

CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demonstrate positive, durable benefits ...
Business Wire

New Study Demonstrates Benefits of Pulmonx Zephyr Endobronchial Valve in Patients with Homogeneous Emphysema

LONDON & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Positive results from the IMPACT study demonstrate that patients with homogeneous emphysema benefit from treatment with Pulmonx Corporation’s ...
Seeking Alpha

Pulmonx: Revisiting Thesis Following Management Change

Pulmonx Corporation's shares have performed poorly over the past year, returning -16%. The company's CEO recently announced his retirement, raising questions about potential changes in corporate ...
Business Wire

Pulmonx® Announces 10,000 Patients Treated with Zephyr® Endobronchial Valves To-Date

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx®, a leader in interventional pulmonology, today announced that 10,000 patients have been treated to-date with its Zephyr® Endobronchial Valve (EBV). The ...